(NASDAQ: KALA) Kala Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 365.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Kala Bio's earnings in 2025 is -$35,841,000.On average, 4 Wall Street analysts forecast KALA's earnings for 2025 to be -$45,604,201, with the lowest KALA earnings forecast at -$51,813,216, and the highest KALA earnings forecast at -$38,377,180. On average, 4 Wall Street analysts forecast KALA's earnings for 2026 to be -$7,402,709, with the lowest KALA earnings forecast at -$9,976,458, and the highest KALA earnings forecast at -$4,551,472.
In 2027, KALA is forecast to generate -$3,349,568 in earnings, with the lowest earnings forecast at -$3,218,212 and the highest earnings forecast at -$3,448,085.